104 results
424B5
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Prospectus supplement for primary offering
4:02pm
;
estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
the potential benefits of strategic collaboration … generally intended to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing
8-K
EX-1.1
CNTA
Centessa Pharmaceuticals plc
13 Sep 24
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
4:00pm
, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand … law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 8(d)(i) above but also the relative fault
424B5
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Prospectus supplement for primary offering
4:40pm
requirements and our needs for additional financing;
the potential benefits of strategic collaboration agreements and our ability to negotiate and enter … to reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a non-U.S. company
S-3ASR
EX-4.6
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Automatic shelf registration
4:01pm
Clause
SECTION 110.
Benefits of Indenture
SECTION 111.
Governing Law
SECTION 112.
Legal Holidays
SECTION 113.
Limited Liability; Immunity of Shareholders … and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.
SECTION 110. Benefits of Indenture. Nothing
S-3ASR
EX-4.4
CNTA
Centessa Pharmaceuticals plc
11 Sep 24
Automatic shelf registration
4:01pm
.
Benefits of Indenture
SECTION 111.
Governing Law
SECTION 112.
Legal Holidays
SECTION 113.
Limited Liability; Immunity of Shareholders, Directors … of the remaining provisions shall not in any way be affected or impaired thereby.
SECTION 110. Benefits of Indenture. Nothing in this Indenture
S-3ASR
4oidudig vi
11 Sep 24
Automatic shelf registration
4:01pm
8-K
EX-99.2
92wa1clno04nhv2
10 Sep 24
Regulation FD Disclosure
7:08am
DEFA14A
nc7amt3cdjx k964mw4
20 May 24
Additional proxy soliciting materials
8:48pm
PRE 14A
xqf43nem 2ox
26 Apr 24
Preliminary proxy
4:36pm
424B5
akk8b8ff boue1j
24 Apr 24
Prospectus supplement for primary offering
8:53pm
8-K
EX-1.1
cmsxxdq
24 Apr 24
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
9:26am
424B5
8ih 3w5tk3kt1xgxv8
23 Apr 24
Prospectus supplement for primary offering
5:16pm
8-K
EX-99.2
br7v84pri yrhxkz
22 Apr 24
Regulation FD Disclosure
7:15am